Alzheimer
Tl;drDes traitements antipsychotiques provoquent des effets secondaires graves chez les personnes atteintes de démence.Les effets secondaires comprennent les crises cardiaques, les fractures et les pneumonies.En France et au Royaume-Uni, seuls deux traitements sont autorisés pour les patients atteints de démence.La prescription des antipsychotiques est en hausse en raison de la crise du Covid.Antipsychotiques et démence : une association préoccupanteL’utilisation de certains médicaments antipsychotiques chez les personnes atteintes de démence donne lieu à d’alarmantes conséquences. Selon une r...
Actusante
Tl;drLes affections neurologiques sont les principales causes de mauvaise santé.Elles ont provoqué 11,1 millions de morts en 2021.43 % de la population mondiale est touchée par une affection neurologique.L’accident vasculaire cérébral est la pire affection neurologique.Les affections neurologiques : un fléau en expansionContrairement aux idées reçues, ce ne sont pas les maladies cardiovasculaires qui détiennent la triste première place des causes de mauvaise santé mondiale, mais bien les affections neurologiques. Selon une récente étude, elles auraient causé “11,1 millions de décès en 2021”. U...
Actusante
Tl;drLes troubles neurologiques sont désormais la principale cause de problèmes de santé.43% de la population mondiale serait touchée par un trouble neurologique en 2021.L’AVC provoque le plus de handicaps et de problèmes de santé.Les troubles neurologiques ont tué plus de onze millions de personnes en 2021.Les troubles neurologiques : une menace silencieuseParmi les fléaux qui affectent l’humanité, les pathologies du système nerveux, de la démence de type Alzheimer aux migraines, en passant par les séquelles d’un accident vasculaire cérébral (AVC), regroupent désormais la majeure partie des p...
24 Matins FR
Washington (AFP) - Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder. Donanemab has been found to slow cognitive decline in the early stages of the disease during a clinical trial -- but there was also a high rate of side effects, including deaths. The Food and Drug Administration (FDA) "has informed Lilly it wants to further understand topics related to evaluating the safety and efficacy of donanemab," the company said in a statement Friday. Th...
AFP
Eine gute Planung ist vor jeder Reise wichtig. Reist ein Angehöriger mit Demenz mit, ist sie aber noch viel wichtiger. Schließlich ist jeder Urlaub ein Ortswechsel - und das kann enormen Stress für Betroffene bedeuten. Muss es aber nicht. Denn so ein gemeinsamer Urlaub kann ihnen das gute Gefühl geben, auch mit der Diagnose Demenz schöne Dinge zu erleben. Und er kann Familien enger zusammenschweißen. Das schreibt die Alzheimer Forschung Initiative (AFI). Drei Fragen und Antworten zum Thema: Wann ist gemeinsames Verreisen möglich, wann nicht? Vor allem im frühen und mittleren Stadium einer Erkr...
DPA (German)
Washington (AFP) - A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday. The US Food and Drug Administration awarded accelerated approval to Aduhelm in June 2021, a decision that was highly contentious at the time because the agency overruled its own independent advisors, who found there was insufficient evidence of benefit. At least three of the 11-member independent committee that voted unanimously against recommending the drug...
AFP
By Nidhi Jacob Donanemab, the latest drug to treat Alzheimer's disease appears to slow cognitive decline by 35%, according to the phase 3 clinical trial results published in the Journal of American Medical Association. While experts have praised the drug's effects, there are safety and cost concerns that loom. Alzheimers is a type of dementia which affects a person's memory, thinking ability and behaviour. The prevalence of Alzheimers in India is 7.4% among adults over the age of 60—meaning about 8.8 million Indians are currently living with dementia, Dr Hrishikesh Sarkar, Senior Consultant, N...
BOOM Live
Washington (AFP) - US pharmaceutical giant Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts despite some patients experiencing serious side effects. In an analysis of nearly 1,200 people in the early stages of the disease, donanemab slowed the progression of symptoms by 35 percent over a period of 18 months compared to placebo. This was measured by cognition and their ability to carry out daily tasks like managing finances, driving, engaging in hobbies and conversing about current...
AFP
Washington (AFP) - US drugmaker Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts. In a placebo controlled trial of nearly 1,200 people with early forms of the disease, donanemab slowed the progression of symptoms by 35 percent over a period of 18 months, as measured by their ability to carry out daily tasks like managing finances, driving, engaging in hobbies and conversing about current events. This follows a 27 percent reduction in decline found for Biogen and Eisai's lecanemab,...
AFP
New York (AFP) - American crooner Tony Bennett has revealed he was diagnosed with Alzheimer's disease in 2016 but kept his condition quiet as he continued to work and tour. The 94-year-old went public in a lengthy feature story published Monday in AARP The Magazine, the widely circulated periodical of the American Association of Retired People. "Life is a gift -- even with Alzheimer's," Bennett tweeted, linking to the article. The hitmaker with a cheery smile has had a particularly strong past decade career-wise despite his condition, becoming the oldest person ever to reach number one on the ...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら